TIME | April 25, 2023
Just as plaintiffs brought a case against the FDA questioning the approval of mifepristone, parties could begin to challenge the FDA’s regulation of off-label use—not only for misoprostol, but for any drug, says Lawrence Gostin, director of the World Health Organization Collaborating Center on National and Global Health Law at Georgetown Law. “If the challenge to mifepristone is successful, it could open the floodgates to litigation against other drugs,” he says.